.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The TRAILBLAZER-ALZ 2 phase 3 trial evaluated donanemab, an antibody designed to clear amyloid plaques, in people with early symptomatic Alzheimer disease and PET evidence of amyloid and tau pathology. Participants receiving donanemab showed significantly less clinical decline than placebo at 76 weeks, with the treatment effect seen in both the low/medium-tau population and the overall study population. The therapy also produced substantial amyloid reduction. However, amyloid-related imaging abnormalities were common, and symptomatic events as well as treatment-related deaths occurred. Donanemab therefore represents a genuine shift toward disease-modifying treatment while simultaneously creating new requirements for diagnostic precision and safety monitoring. For HCPs, the practical message is that anti-amyloid therapy is not simply another symptomatic drug. Patients need biomarker confirmation, assessment of treatment eligibility and vascular risk, serial MRI surveillance, and clear counselling about expected benefits and potential harms. The trial also supports a broader shift toward treating Alzheimer disease earlier, before substantial functional decline has occurred. The evidence is therefore relevant both to dementia diagnosis and to therapeutic decision-making.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The TRAILBLAZER-ALZ 2 phase 3 trial evaluated donanemab, an antibody designed to clear amyloid plaques, in people with early symptomatic Alzheimer disease and PET evidence of amyloid and tau pathology. Participants receiving donanemab showed significantly less clinical decline than placebo at 76 weeks, with the treatment effect seen in both the low/medium-tau population and the overall study population. The therapy also produced substantial amyloid reduction. However, amyloid-related imaging abnormalities were common, and symptomatic events as well as treatment-related deaths occurred. Donanemab therefore represents a genuine shift toward disease-modifying treatment while simultaneously creating new requirements for diagnostic precision and safety monitoring. For HCPs, the practical message is that anti-amyloid therapy is not simply another symptomatic drug. Patients need biomarker confirmation, assessment of treatment eligibility and vascular risk, serial MRI surveillance, and clear counselling about expected benefits and potential harms. The trial also supports a broader shift toward treating Alzheimer disease earlier, before substantial functional decline has occurred. The evidence is therefore relevant both to dementia diagnosis and to therapeutic decision-making.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
2 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
4 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
3 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
3 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
4 days back
